AVENTRIX - PHARMA - Hohes Kurs-Potenzial $$

[JohnJohnson]

ADVENTRX mit Potenzial
Nach Ansicht der Experten von "Global Biotech Investing" bietet die Aktie von ADVENTRX Pharmaceuticals (ISIN US00764X1037/ WKN 473583) Potenzial.

Das Unternehmen habe einen Ausblick auf die laufenden Forschungsreihen mit Co-Factor abgegeben. Die Wertpapierexperten hätten zuletzt bereits von den starken Ergebnissen berichtet, welche die Gesellschaft kurz zuvor bekannt gegeben habe. Vergangene Woche sei nun bekannt geworden, dass man bereits mehr als die Hälfte der für die Phase IIb-Tests geplanten Patienten registriert habe.


Außerdem treibe das Unternehmen nun die Phase III-Tests voran und rechne mit einer 1.200 Patienten starken Studie bei der Behandlung von metastasenbildendem Darmkrebs. Außerdem plane man eine Studie bei der Behandlung von fortgeschrittenem Brustkrebs an 450 Patientinnen.

Mit der Fortis-Bank habe nun ein weiteres Investmenthaus die Aktie analysiert und ein Kursziel von 6 USD ausgegeben. Bis dahin wären noch einmal 40 Prozent, bis zum Kursziel von Dawson James bei 9 USD sogar rund 100 Prozent zu holen.

Die Experten von "Global Biotech Investing" sehen bei der ADVENTRX-Aktie Kurspotenzial.
Quelle: GLOBAL BIOTECH I...


hier könnte man als anleger sicher am algemeiene aufwärtstrend der bios überschnittlich gut partizipieren.


hab mich heute eingedeckt, könnte noch mal bis auf 3€ rücksetzer geben, zum nachkauf optimal.

was meint ihr dazu????

[JohnJohnson]

ADVENTRX Pharmaceuticals to Present at the OneMedForum Finance Conference on January 13





SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present at the OneMedForum Finance Conference on Wednesday, January 13, 2010, at 4:30 p.m. Pacific time. The conference will be held at the Sir Francis Drake Hotel in San Francisco

Interested parties can access a live audio webcast on the ADVENTRX Pharmaceuticals Web site at http://www.adventrx.com/. An archived presentation will be available on the Web site for 30 days

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's Web site at http://www.adventrx.com/.

DATASOURCE: ADVENTRX Pharmaceuticals, Inc


CONTACT: Brian Culley, Principal Executive Officer of ADVENTRX

Pharmaceuticals, +1-858-552-0866, or Investors, Don Markley of

Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, , for

ADVENTRX Pharmaceuticals, Inc


Web Site: http://www.adventrx.com/

[JohnJohnson]

NEWS $$$$ ADVENTRX Pharmaceuticals Announces Closing of Financing


SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has completed the previously announced sale of shares of its Series E convertible preferred stock pursuant to a registered direct offering to institutional investors, representing gross proceeds to ADVENTRX of approximately $19 million. ADVENTRX plans to use the net proceeds from the offering to fund activities relating to the commercial launch of ANX-530, including acquiring or developing sales, marketing and distribution capabilities and the associated regulatory compliance infrastructure, and to continue the development of ANX-514 in the United States, and for general corporate purposes

The convertible preferred stock is convertible into shares of ADVENTRX's common stock at the option of the investors at a conversion price of $0.38115 per share and will accrue a 3.73344597664961% cumulative dividend until January 7, 2015. If the convertible preferred stock is converted at any time prior to January 7, 2015, ADVENTRX will pay the holder an amount equal to the total dividend that would accrue on the convertible preferred stock from the conversion date through January 7, 2015, or $186.67 per $1,000 stated value of convertible preferred stock converted, less any dividend payments made with respect to the converted convertible preferred stock. Approximately $3.5 million of the gross proceeds will be placed in an escrow account, which amounts will be released to make the dividend and other payments described above

The investors also will receive warrants to purchase an aggregate of 12,462,285 shares of ADVENTRX's common stock. The warrants will have an exercise price of $0.3499 per share and are exercisable at any time after the closing of the transaction and before the thirty (30) month anniversary of the initial exercise date

The convertible preferred stock and warrants are being offered by ADVENTRX pursuant to effective registration statement(s) on Form S-3 filed with the Securities and Exchange Commission ("SEC"). A prospectus relating to the offering was filed with the SEC on January 4, 2010. Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), acted as the exclusive placement agent for the transaction

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities may only be offered by means of a prospectus. Copies of the prospectus can be obtained directly from Rodman & Renshaw, LLC at 1251 Avenue of the Americas, 20th Floor, New York, NY 10020, or from the SEC's website at http://www.sec.gov/

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at http://www.adventrx.com/

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the potential for regulatory authorities to require additional preclinical work and/or clinical activities to support regulatory filings; the risk the FDA will determine that ANX-530 and Navelbine® are not bioequivalent or for the FDA to require additional preclinical work and/or clinical activities to support the acceptance or approval of an ANX-530 NDA; the risk that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials, and that FDA may require ADVENTRX to perform additional non-clinical or clinical studies; difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ANX-530, including validating commercial manufacturers and suppliers; the risk that ADVENTRX's common stock will be delisted by the NYSE Amex, including as a result of failing to maintain sufficient stockholders' equity or a sufficient stock price; the risk that the provisions of Delaware General Corporation Law will prohibit ADVENTRX from making the cumulative dividend and other payments due its Series E convertible preferred stock (or to the holders thereof), which may be a breach of its certificate of incorporation or other contractual obligations and expose ADVENTRX to corresponding liability; the risk that the performance of third parties on whom ADVENTRX relies to conduct its studies or evaluate the data may be substandard, or they may fail to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and in the prospectus relating to this offering that was filed with the Securities and Exchange Commission on January 4, 2010. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.

DATASOURCE: ADVENTRX Pharmaceuticals, Inc


CONTACT: Brian Culley, Principal Executive Officer of ADVENTRX

Pharmaceuticals, +1-858-552-0866; or Investors, Don Markley of

Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, , for

ADVENTRX Pharmaceuticals, Inc


Web Site: http://www.adventrx.com/




20 GOOD things about ANX:

FROM SOMEONE I TRUST

1) No debt
2) NOT a high float
3) GOOD pre-clinical test results with their drug.
4) NDA then FDA

[JohnJohnson]

Over BILLION in possible new sells, and, the market cap is $47 million of now.We got a big big winner here.

[JohnJohnson]

NEW BULLISH write UP on ANX - http://www.examiner.com/x-3765-Denver-Stock-Market-Examiner~y2010m1d7-Most-volatile-stock-under-1-could-fly-now-that-financing-has-been-completed

[JohnJohnson]

Finanzierung abgeschossen.Übernahmespekulationen.
Shortys must be cover. posssibe here are Chances for pps about over 2 US$++

ANX - HOT HOT HOT

[JohnJohnson]

NEWS $$ Press Release Source: Beacon Equity On Friday January 8, 2010, 6:50 am EST

DALLAS, Jan. 8, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotechnology company Adventrx Pharmaceuticals Inc. (AMEX:ANX - News). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.


The full report is available at: http://www.beaconequity.com/i/ANX

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Adventrx Pharmaceuticals Inc. (ANX) engages in the in-licensing, development and commercialization of cancer-related proprietary drug therapies. The Company seeks to improve upon existing treatments of cancer.

In the report, the analyst notes:

"According to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. If approved by the U.S. Food and Drug Administration (FDA), the market for the Company's drug candidates, has a potential to reach more than $1.0 billion at market saturation.

"The Company's strategy is to take advantage of an effective lifecycle-management technique of reformulating existing successfully marketed drug therapies. Of the top 50 pharmaceutical companies, more than 40% of all drug therapies produced have been reformulated to extend the life of existing marketed drugs between the years 2002 and 2005. Patent expirations and competition are threats to all pharmaceutical companies. Modified and improved existing products have become an important technique as a method of improving revenue stream for longer time periods."

To read the entire report visit: http://www.beaconequity.com/i/ANX

See what investors are saying about these stocks at penny stock forum.

BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

[JohnJohnson]

ALL Longs need to watch this: http://www.adventrx.com/flash/Vinorelbine.swf



OneMedForum Finance Conference 2010
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$


http://www.onemedplace.com/onemedforum/

Held annually in San Francisco, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners. Over 100 company presentations will occur by some of the most promising - and typically least recognized - companies in the world. Recognizing the impacts and opportunities connected to healthcare reform and the stimulus package, we have added a third day dedicated to Health Information. Join us at The Sir Francis Drake Hotel, as it will be the destination for those who are interested in emerging healthcare and life sciences companies.

PRESENTING COMPANIES : http://www.onemedplace.com/onemedforum/companies.php



http://finance.aol.com/company/adventrx-pharmaceuticals-inc/anx/ase/institutional-ownership

[JohnJohnson]

ANX / Link for Wednesday !

Webcast
ADVENTRX PHARMACEUTICALS INC at OneMedPlace Finance Forum (Live)
01/13/10 at 4:30 p.m. PT

http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-IRHome
http://ir.adventrx.com/phoenix.zhtml?p=irol-eventDetails&c=75414&eventID=2664535

[JohnJohnson]

M.E. Garza's article on ANX from December 29, 2009:

http://seekingalpha.com/article/180106-adventrx-pharmaceuticals-gains-nearly-63-still-looking-for-more

A quote from BRIAN M. CULLEY (Principal Executive Officer) from a Wall Street interview held on October 19, 2009:

"TWST: How would you like to see the company evolve over the next couple of years?
Mr. Culley: We’re strongly committed to creating value for ADVENTRX stockholders. That might mean we will be acquired or will remain as an independent business, and we will make those determinations as we grow, but we will always make the decision that we believe maximizes our value on a risk-adjusted basis".

http://www.adventrx.com/assets/pdfs/ANX-TWST-Oct09-FINAL.pdf

[JohnJohnson]

ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) Reuters ProVestor Plus Company Report
Industry Profitability
8 January, 2010 Page 8
TTM = Trailing Twelve Month. MRQ = Most Recent Quarter.
Financial Strength
ANX Industry Sector S&P 500 Company Rank in Industry
Quick Ratio 1.7 3.1 2.3 1.5 51
Current Ratio 1.7 3.7 3.0 2.0 46
Total Debt to Equity 0.0 0.4 0.5 0.8 NA
Long Term Debt to Equity 0.0 0.3 0.4 0.6 NA
Interest Coverage for Trailing Twelve Months (338.9) 2.1 19.3 10.9 5
Worst Best
Values are for Most Recent Quarter unless noted otherwise. ADVENTRX Pharmaceuticals, Inc. is less leveraged than the average for the
Biotechnology & Drugs industry.
Growth Rates (%)
% Growth Rate ANX Industry Sector S&P 500 Company Rank in Industry
Sales Growth For Most Recent Quarter NA 14.6 6.0 (6.7) NA
Sales Growth For Trailing 12 Months (40.0) 11.1 3.4 (5.6) 18
Sales Growth For Past 5 Years 162.7 27.3 15.3 13.0 98
Capital Spending Growth for Past 5 Years 32.4 10.0 6.5 12.2 76
EPS Growth for Most Recent Quarter 69.6 25.5 23.6 (0.3) 77
EPS Growth for Trailing Twelve Months 33.0 17.7 16.0 (15.0) 62
EPS Growth for Past 5 Years NA 30.5 20.8 16.8 NA
Worst Best

ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) Reuters ProVestor Plus Company Report
Annual Financial Statements
8 January, 2010 Page 9
Years are Fiscal Years.
Currency in Thousands of U.S. Dollars (except per share values). Shares in Thousands.
Annual Income Statement
2001 2002 2003 2004 2005 2006 2007 2008
12 Months 12 Months 12 Months 12 Months 12 Months 12 Months 12 Months 12 Months
Dec. 31, 2001 Dec. 31, 2002 Dec. 31, 2003 Dec. 31, 2004 Dec. 31, 2005 Dec. 31, 2006 Dec. 31, 2007 Dec. 31, 2008
Restated as of Restated as of
Dec. 31, 2007 Dec. 31, 2007
Licensing revenue $0 $46 $4 $0 $0 $0 $500 $500
Total Revenue $0 $46 $4 $0 $0 $0 $500 $500
General/Admin. $2,038 $1,388 $1,586 $4,018 $4,901 $7,236 $8,679 $9,720
Research/Development 946 283 749 2,744 8,682 12,001 15,934 17,922
Depreciation/Amort. 7,672 428 9 41 116 177 198 168
Interest Expense 12 54 1 0 0 0 0 0
In process research and
development NA NA NA 0 0 10,422 0 0
Goodwill Impairment 5,702 NA NA 0 NA NA 0 0
Total Operating Expense $16,370 $2,153 $2,345 $6,803 $13,699 $29,836 $24,811 $27,810
Interest Income $32 $1 $9 $103 $496 $1,165 $2,169 $550
Other Income NA NA NA NA NA NA 0 112
Net Income Before Taxes ($16,338) ($2,106) ($2,332) ($6,700) ($13,203) ($28,671) ($22,142) ($26,648)
Net Income After Taxes ($16,338) ($2,106) ($2,332) ($6,700) ($13,203) ($28,671) ($22,142) ($26,648)
Net Income Before Extra. Items ($16,338) ($2,106) ($2,332) ($6,700) ($13,203) ($28,671) ($22,142) ($26,648)
Net Income ($16,338) ($2,106) ($2,332) ($6,700) ($13,203) ($28,671) ($22,142) ($26,648)
Preferred Dividends ($256) ($242) ($38) $0 $0 $0 $0 $0
EPS Reconciliation
2001 2002 2003 2004 2005 2006 2007 2008
Income Available to Com Excl
ExtraOrd ($16,594) ($2,348) ($2,370) ($6,700) ($13,203) ($28,671) ($22,142) ($26,648)
Income Available to Com Incl
ExtraOrd ($16,594) ($2,348) ($2,370) ($6,700) ($13,203) ($28,671) ($22,142) ($26,648)
Basic Weighted Average Shares 14,805 15,682 31,798 50,720 59,828 73,988 89,913 90,253
Basic EPS Excluding ExtraOrdinary
Items ($1.12) ($0.15) ($0.07) ($0.13) ($0.22) ($0.39) ($0.25) ($0.30)
Basic EPS Including ExtraOrdinary
Items ($1.12) ($0.15) ($0.07) ($0.13) ($0.22) ($0.39) ($0.25) ($0.30)
Diluted Net Income ($16,594) ($2,348) ($2,370) ($6,700) ($13,203) ($28,671) ($22,142) ($26,648)
Diluted Weighted Average Shares 14,805 15,682 31,798 50,720 59,828 73,988 89,913 90,253
Diluted EPS Excluding ExtraOrd Items ($1.12) ($0.15) ($0.07) ($0.13) ($0.22) ($0.39) ($0.25) ($0.30)
Diluted EPS Including ExtraOrd Items ($1.12) ($0.15) ($0.07) ($0.13) ($0.22) ($0.39) ($0.25) ($0.30)
Normalized Income Before Taxes ($3,033) ($2,106) ($2,332) ($6,700) ($13,203) ($18,249) ($22,142) ($26,648)
Normalized Income After Taxes ($3,033) ($2,106) ($2,332) ($6,700) ($13,203) ($18,249) ($22,142) ($26,648)
Normalized Inc. Avail to Com. ($3,289) ($2,348) ($2,370) ($6,700) ($13,203) ($18,249) ($22,142) ($26,648)
Basic Normalized EPS ($0.22) ($0.15) ($0.07) ($0.13) ($0.22) ($0.25) ($0.25) ($0.30)
Diluted Normalized EPS ($0.22) ($0.15) ($0.07) ($0.13) ($0.22) ($0.25) ($0.25) ($0.30)
Trend Graphs on next page
ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) Reuters ProVestor Plus Company Report
Annual Financial Statements
8 January, 2010 Page 10
Years are Fiscal Years.
Currency in Thousands of U.S. Dollars (except per share values). Shares in Thousands.
Income Statement Trend Graphs
Bar graphs of specific Income Statement items can be used to help in identifying volatility.
Fiscal Year 2008
Fiscal Year 2007
Fiscal Year 2006
Fiscal Year 2005
Fiscal Year 2004
Fiscal Year 2003
Fiscal Year 2002
Fiscal Year 2001
NM
NM
NM
NM
NM
NM
NM
NM
($0.30)
($0.25)
($0.39)
($0.22)
($0.13)
($0.07)
($0.15)
($1.12)
$500
$500
$0
$0
$0
$4
$46
$0
NA
NA
NM
NM
NM
NA
NA
NM
Annual EBITD Margin (%) EPS Diluted (Excl. Extraord.) Net Annual Revenue Annual Gross Margin (%)
ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) Reuters ProVestor Plus Company Report
Annual Financial Statements
8 January, 2010 Page 11
Years are Fiscal Years.
Currency in Thousands of U.S. Dollars. Shares in Thousands.
Annual Balance Sheet
2001 2002 2003 2004 2005 2006 2007 2008
As of As of As of As of As of As of As of As of
Dec. 31, 2001 Dec. 31, 2002 Dec. 31, 2003 Dec. 31, 2004 Dec. 31, 2005 Dec. 31, 2006 Dec. 31, 2007 Dec. 31, 2008
Reclassified as of
Assets Dec. 31, 2007
Cash and cash equivalents $164 $104 $4,226 $13,032 $14,635 $25,974 $14,781 $9,850
Shortterm investments NA NA NA 0 7,958 25,771 18,682 0
Notes Rcvbl. 36 0 NA NA NA NA NA NA
Prepaid Expenses 0 0 28 115 256 511 616 478
Advances to Emp. 30 0 NA NA NA NA NA NA
Interest and other receivables NA NA 0 11 10 80 72 122
Assets Available for Sale NA NA 0 108 0 NA NA NA
Total Current Assets $230 $104 $4,254 $13,266 $22,859 $52,336 $34,151 $10,450
Furnit./Equip. $32 $32 $48 $333 $513 $651 $755 $720
Computer Softwar 9 12 12 12 65 99 122 103
Depreciation (28) (30) (39) (60) (170) (347) (545) (625)
Other Assets 34 13 8 57 355 58 58 61
Total Assets $277 $131 $4,283 $13,608 $23,622 $52,797 $34,541 $10,709
Liabilities
Payable/Accrued $430 $579 $90 $532 $593 $480 $552 $1,721
Accrued Salary 304 115 0 57 173 293 623 915
Accrued Liabilities NA NA 0 629 930 1,675 2,318 2,077
Curr.Port.NP 54 197 0 NA NA NA NA NA
Accrued Dividend 128 35 73 0 NA NA NA NA
Warranty Liability NA NA NA 0 29,696 NA NA NA
Total Current Liabilities $916 $926 $163 $1,218 $31,392 $2,448 $3,493 $4,713
Notes Payable $0 $57 $0 NA NA NA NA NA
Total Long Term Debt 0 57 0 NA NA NA NA NA
Other Long Term Liabilites NA NA NA 0 57 36 14 0
Total Liabilities $916 $983 $163 $1,218 $31,449 $2,484 $3,507 $4,713
Shareholder Equity
Sr. B Conv. Prfd $0 $2 $2 $0 $0 NA NA NA
Sr. C Conv. Prfd 0 1 0 0 0 NA NA NA
Common Stock 15 17 42 54 67 90 90 90
Paid in Capital 23,390 25,276 32,557 47,553 52,105 127,284 130,141 131,751
Accum Deficit (24,043) (26,149) (28,481) (35,182) (59,965) (77,057) (99,199) (125,846)
Treasury Stock NA NA 0 (35) (35) NA NA NA
Accumulated other comprehensive
income ( NA NA NA 0 (2) (2) 3 0
Total Equity ($638) ($853) $4,120 $12,390 ($7,830) $50,315 $31,035 $5,995
Total Liabilities & Shareholders'
Equity $278 $130 $4,283 $13,608 $23,619 $52,799 $34,542 $10,708
S/O-Common Stock 15,005 17,496 42,492 53,834 56,506 89,677 90,253 90,253
Total Common Shares
Outstanding 15,005 17,496 42,492 53,834 56,506 89,677 90,253 90,253
T/S-Common Stock NA NA 0 23 23 0 0 0
S/O-Sr. A. Conv. Prfd. Stk. 3 0 0 0 NA NA NA NA
S/O-Sr. B. Conv. Prfd. Stk. 200 200 200 0 NA NA NA NA
S/O-Sr. C. Conv. Prfd. Stk. 0 70 0 0 NA NA NA NA
Total Preferred Shares Outstanding 203 271 200 0 NA NA NA NA
Trend Graphs on next page
ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) Reuters ProVestor Plus Company Report
Annual Financial Statements
8 January, 2010 Page 12
Years are Fiscal Years.
Currency in Thousands of U.S. Dollars. Shares in Thousands.
Balance Sheet Trend Graphs
Bar graphs of specific Balance Sheet items can be used to help in identifying volatility.
Fiscal Year 2008
Fiscal Year 2007
Fiscal Year 2006
Fiscal Year 2005
Fiscal Year 2004
Fiscal Year 2003
Fiscal Year 2002
Fiscal Year 2001
$9,850
$14,781
$25,974
$14,635
$13,032
$4,226
$104
$164
$4,713
$3,507
$2,484
$31,449
$1,218
$163
$983
$916
$5,995
$31,035
$50,315
($7,830)
$12,390
$4,120
($853)
($638)
90,253
90,253
89,677
56,506
53,834
42,492
17,496
15,005
Cash and Equivalents Total Liabilities Total Equity Shares Outstanding
ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) Reuters ProVestor Plus Company Report
Annual Financial Statements
8 January, 2010 Page 13
Years are Fiscal Years.
Currency in Thousands of U.S. Dollars.
Annual Cash Flow Statement
2001 2002 2003 2004 2005 2006 2007 2008
12 Months 12 Months 12 Months 12 Months 12 Months 12 Months 12 Months 12 Months
Dec. 31, 2001 Dec. 31, 2002 Dec. 31, 2003 Dec. 31, 2004 Dec. 31, 2005 Dec. 31, 2006 Dec. 31, 2007 Dec. 31, 2008
Reclassified as of Reclassified as of
Cash From (Used By) Operations Dec. 31, 2007 Dec. 31, 2007
Net Income ($16,339) ($2,106) ($2,332) ($6,701) ($13,203) ($28,672) ($22,142) ($26,647)
Depreciation 7,618 33 9 41 116 177 198 168
Gain on disposal of fixed assets NA NA NA NA NA NA 0 (4)
Forgiveness Advance 0 30 0 0 NA NA NA NA
Goodwill Impairment 5,702 NA 0 0 NA NA NA NA
Write off of Assets AFS NA NA 0 0 108 0 0 NA
In-process research and
development NA NA NA NA 0 10,422 0 NA
Amort. Debt Discount 54 396 0 0 NA NA NA NA
Expense Paid Warrant 167 163 157 86 NA NA NA NA
Expense Paid Prfd. 137 6 0 0 NA NA NA NA
Exp. Rel. to Options 0 329 286 525 995 1,894 2,414 1,606
Expenses Rel. Options issd Non
Employees NA NA 0 0 94 104 2 5
Expenses paid by issuance of
common NA NA 0 0 102 147 78 0
Accretion of Discounts NA NA 0 0 (112) (243) (1,042) (208)
Issuance of Common 387 12 207 0 NA NA NA NA
Prepaid Assets NA 0 (23) (255) (281) (107) (174) 86
Other Assets 12 (9) 0 0 57 (21) (21) (14)
Increase in accounts payable and
accrued 550 44 (550) 1,128 479 525 1,044 1,221
Cash from Operating Activities ($1,712) ($1,102) ($2,246) ($5,176) ($11,645) ($15,774) ($19,643) ($23,787)
Plus: Cash From (Used By) Investment Activities
Capital Expenditure ($16) ($2) ($16) ($306) ($238) ($172) ($127) ($65)
Cash paid for acquisitions net of
cash NA NA NA NA 0 (32) 0 NA
Proceeds from sale of property and
equip NA NA NA NA NA NA 0 34
Mat. Certificates 1,016 NA NA NA NA NA NA NA
Proceeds from Sale of Short Term
Inv. NA NA 0 0 5,275 15,030 59,240 33,244
Purchase of Short Term Invesetment NA NA 0 0 (13,123) (32,600) (51,104) (14,356)
Cash Acquired (35) NA NA NA NA NA NA NA
Notes Rcvbl. NA 36 0 NA NA NA NA NA
Cash from Investing Activities $965 $34 ($16) ($306) ($8,086) ($17,774) $8,009 $18,857
Plus: Cash From (Used By) Financing Activities
Finance Payment NA NA $0 ($1,367) ($1,883) ($3,135) $0 NA
Proceeds from sale of common stock NA 0 6,590 15,626 19,999 39,999 0 NA
Sale of Prfd. Stock 0 1,002 0 NA NA NA NA NA
Exercise of Stock Options NA NA 0 0 145 126 442 0
Exerecise of Warrant 48 287 NA 27 3,073 7,898 0 NA
Purchase of Warrants (55) NA 50 0 0 NA NA NA
Issuance of LT Debt 450 NA NA NA NA NA NA NA
Payment of LT Debt NA (280) (254) 0 NA NA NA NA
Cash from Financing Activities $443 $1,009 $6,386 $14,286 $21,334 $44,888 $442 $0
Equals: Increase (Decrease) In Cash
Net Change in Cash ($303) ($61) $4,122 $8,806 $1,602 $11,339 ($11,193) ($4,931)
Net Cash - Beginning Balance $468 $164 $104 $4,226 $13,032 $14,635 $25,974 $14,781
Net Cash - Ending Balance 164 104 4,226 13,032 14,634 25,974 14,781 9,850
Cash Interest Paid 3 7 1 0 0 0 0 0
Trend Graphs on next page

[JohnJohnson]

Beacon Equity Report on ANX

excerpt:

According to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. If approved by the U.S. Food and Drug Administration (FDA), the market for the Company’s drug candidates has a potential to reach more than $1.0 billion at market saturation.

Pharmaceutical companies with revenue of more than $1 billion include Cephalon Inc. (Nasdaq: CEPH), which trades at a market capitalization of $4.73 billion, and King Pharmaceuticals (Nasdaq: KG), which trades at a market capitalization of $3.15 billion. As of January 6, ANX trades at a market capitalization of $50.7 million.

The Company is in the process of commercializing two drug-therapy candidates in late stages of Food and Drug administration (FDA) clinical trials in the United States. The Company’s two candidates include ANX-530 (vinorelbine emulsion) and ANX-514 (docetaxel emulsion), formulated to enhance certain standard-of-care chemotherapy drugs. The Company also states that ANX-530 and ANX-514 are safer, more convenient and less expensive than Navelbine and Taxotere, two drug therapies currently marketed.

The Company’s strategy is to take advantage of an effective lifecycle-management technique of reformulating existing successfully marketed drug therapies. Of the top 50 pharmaceutical companies, more than 40% of all drug therapies produced have been reformulated to extend the life of existing marketed drugs between the years 2002 and 2005. Patent expirations and competition are threats to all pharmaceutical companies. Modified and improved existing products have become an important technique as a method of improving revenue stream for longer time periods.

The Company believes that chemotherapy drugs Navelbine and Taxotere have limitations that can be improved upon with its novel technologies. A new formulation of these two popular standard-of-care drug therapies is expected to reduce side-effects, negative results and medical complications of patients suffering from cancer.

The Company has attracted capital from Icahn Capital Management, Carl Icahn (as an individual), Barclays Global Investors UK Holdings, Vanguard Group among other well-know investors and group holding companies.

Recent Company News

On January 6, the Company announced that it will present at the OneMedForum Finance Conference at the Sir Francis Drake Hotel in San Francisco on January 13, 2010.

http://www.beaconequity.com/technical-trading-overview-for-adventrx-pharmaceuticals-inc-anx-2/



do your own research
ADVENTRX Pharmaceuticals, Inc. (ANX) Stock Trading Info:




Public Reply | Private Reply | Keep | Last Read Next 10 | Previous | Next
Add ADVENTRX Pharmaceuticals, Inc. (ANX) To Favorites Keyboard Shortcuts
Report TOS Violation


X
Current Price
Change
Volume
Detailed Quote - Discussion Board

+/- to Watchlist

[JohnJohnson]

http://seekingalpha.com/instablog/503983-tmackie/42955-adventrx-pharmaceuticals-anx-submits-cancer-drug-to-nda-amid-takeover-rumors

ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX)
ADVENTRX Pharmaceuticals
is a biopharmaceutical company founded in 1995 and based in San Diego, California, which focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. The Company recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530, a novel emulsion formulation of chemotherapy drug Vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with Cisplatin, as well as to treat advanced or metastatic breast cancer.

If approved, ANX-530 threatens to take market share away from several bigger pharmaceutical companies, including GlaxoSmithKline. This could mean a huge upside to the current share price, especially since the Company has no debt and a low float, as well as millions of cash on hand. Among ADVENTRX's top institutional holders are Carl Icahn's Icahn Capital Management, Renaissance Technologies, UBS AG, the Bank of New York Mellon and Barclay's Global Investors. Beacon Equity Research has the stock listed as "Bullish."

The Company's Principal Executive Officer, Brian M. Culley, will be presenting at the OneMedForum Finance Conference on Wednesday, January 13, 2010. Mr. Culley will be discussing ANX-530 as well as another late-stage product candidate, ANX-514 (3 Billion existing market), which is a novel emulsion formulation of the chemotherapy drug Docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers.

When interviewed for this article, Principal Executive Officer, Brian Culley was asked about Carl Icahn's interest in the company. Mr. Culley confirmed, "We are well aware that Carl Icahn is a substantial stockholder in ADVENTRX." He went on to add, "In fact, the Icahn affiliates are entitled to have one seat on our board of directors."

Shares of ANX have been volatile amid news of takeover rumors recently reported by Fox Business. When asked about the takeover rumors, Mr. Culley responded, "No comment." This will only serve to fuel the speculation.


Disclosure: Disclosure: Long ANX

[JohnJohnson]

SOMETHING BIG IS COMING

PRESIDENT COMMENTS ON TAKE-OVER

http://seekingalpha.com/instablog/503983-tmackie/42955-adventrx-pharmaceuticals-anx-submits-cancer-drug-to-nda-amid-takeover-rumors

[JohnJohnson]

Article just out on ANX - LINK attached!
http://newsblaze.com/story/20100110141726trho.nb/topstory.html

Make sure to hit the "buzz up" button on the top right.

Or hit buzz up here:
http://buzz.yahoo.com/article/1:8ccfb0687deca3b804785f66e2aa8ad1:e51d620309c6333 b3da0ecd86c0c6ebc/Adventrx-Pharmaceuticals-ANX-Submits-Cancer-Drug-to-NDA-Amid-Takeover-Rumors?fru=1

It's the real deal, guys. This is a great article for LONGS. Again, Buzz it up so it gets to most popular.

You can also find it on Google Finance:
http://www.google.com/finance/company_news?q=AMEX:ANX


Adventrx Pharmaceuticals (ANX) Submits Cancer Drug to NDA Amid Takeover Rumors:


ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX) is a biopharmaceutical company founded in 1995 and based in San Diego, California, which focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. The Company recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530, a novel emulsion formulation of chemotherapy drug Vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with Cisplatin, as well as to treat advanced or metastatic breast cancer.

If approved, ANX-530 threatens to take market share away from several bigger pharmaceutical companies, including GlaxoSmithKline. This could mean a huge upside to the current share price, especially since the Company has no debt and a low float, as well as millions in cash on hand. Among ADVENTRX's top institutional holders are Carl Icahn's Icahn Capital Management, Renaissance Technologies, UBS AG, the Bank of New York Mellon and Barclay's Global Investors. Beacon Equity Research has the stock listed as "Bullish."

The Company's Principal Executive Officer, Brian M. Culley, will present at the OneMedForum Finance Conference on Wednesday, January 13, 2010. Mr. Culley will discuss ANX-530 as well as another late-stage product candidate, ANX-514 (3 Billion existing market), which is a novel emulsion formulation of the chemotherapy drug Docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers.

When interviewed for this article, Principal Executive Officer, Brian Culley was asked about Carl Icahn's interest in the company. Mr. Culley confirmed, "We are well aware that Carl Icahn is a substantial stockholder in ADVENTRX." He went on to add, "In fact, the Icahn affiliates are entitled to have one seat on our board of directors."

Shares of ANX have been volatile amid news of takeover rumors recently reported by Fox Business. When asked about the takeover rumors, Mr. Culley responded, "No comment." This will only serve to fuel the speculation.

Traci Hogg is a small stock trader and business writer, who specializes in investigating successful OTC companies.

Disclosure: Writer is Long ANX, but receives no compensation from the company

LINK:
http://newsblaze.com/story/20100110141726trho.nb/topstory.html

[JohnJohnson]

ANX - Hot Tip on Walstreet - Here comes the $$$++

[JohnJohnson]

Sit back, relax and watch it go to $5.00.
My broker told me about this stock and am lovin' it!
Buyout is imminent! What will it be at $10 or more?

[JohnJohnson]

ANX

I love it .-ANX exploding soon and the BIG RUN is coming soon

http://www.phasebiotech.com/2010/01/adventrx-makes-good-on-their-promise.html

[JohnJohnson]

Alert run to grab ANX before dollars level

[JohnJohnson]

NEWS?? This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

GSK forges strategic collaboration agreement with Adventrx Pharmaceuticals, Inc. (ANX)

Issued: Monday 11th January 2010, London UK

GSK announced that it entered into a strategic relationship with Adventrx Pharmaceuticals, Inc. (ANX) and the acquisition of a minority shareholding in the San Diego, CA based pharmaceuticals company. This is part of a wide ranging agreement which includes combining commercial activities in Europe and the United States and the divestment of several assets to GSX.

On completion, GSX issued 2.5 million ordinary shares to Adventrx in consideration for the transfer of assets. .......

In addition, Abbas Hussain, President Emerging Markets, GlaxoSmithKline will be appointed to Aspen’s Board of Directors as a non-executive director with effect from 7th December.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.

[JohnJohnson]

market cap only $69 million,, with approval could see $5.00 pps

[JohnJohnson]

ANX @ OneMedForum Finance Conference on Jan 13

SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present at the OneMedForum Finance Conference on Wednesday, January 13, 2010, at 4:30 p.m. Pacific time. The conference will be held at the Sir Francis Drake Hotel in San Francisco.

Interested parties can access a live audio webcast on the ADVENTRX Pharmaceuticals Web site at www.adventrx.com. An archived presentation will be available on the Web site for 30 days.

LINK:
http://finance.yahoo.com/news/ADVENTRX-Pharmaceuticals-to-prnews-3163353661.html?x=0&.v=1

[JohnJohnson]

http://www.mffais.com/anx

[JohnJohnson]

JP MORGAN ON OUR SIDE - To the Party soon - Nice $$$


ARTICLE 1/13/10 LINK - $1.85 soon!
http://www.xconomy.com/san-diego/2010/01/13/once-destined-for-bankruptcy-adventrx-pharmaceuticals-sets-new-course-with-reformulated-drugs/

Here are some highlights:

As for the Internet rumors and investor hype that has accompanied the biotech’s resurrection, Culley says Adventrx has not funded any financial research and doesn’t “solicit those kinds of reports.” He adds that many Adventrx shareholders are individual investors who might not be as sophisticated as institutional investors. Still, Culley says, “The various reports and exceedingly high volume, I feel confident, are being driven by a compelling and attractive story.”

As for institutional investors, Culley acknowledges that Carl Icahn made a sizable investment in Adventrx in 2005 and still holds a roughly 3 percent stake in the company. Culley says Icahn is “one of our largest shareholders, and the only investment entity with a board seat.” That seat was filled for three years by Alex Denner, who also represents Icahn’s investment entities on the boards of Cambridge, MA-based Biogen Idec and San Diego’s Amylin Pharmaceuticals. But Culley says Denner resigned late last year “without disputes,” and “before the company started kind of waking up and running again.”

Culley noted that Icahn started investing in Adventrx when its common stock was trading at $1.85 a share. Since then, Adventrx has fallen as low as 3 cents a share. But Culley says, “I’d like to get him [Icahn] back in the black again.”


ANX @ OneMedForum Finance Conference on Jan 13

SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present at the OneMedForum Finance Conference on Wednesday, January 13, 2010, at 4:30 p.m. Pacific time. The conference will be held at the Sir Francis Drake Hotel in San Francisco.

Interested parties can access a live audio webcast on the ADVENTRX Pharmaceuticals Web site at www.adventrx.com. An archived presentation will be available on the Web site for 30 days.

LINK:
http://finance.yahoo.com/news/ADVENTRX-Pharmaceuticals-to-prnews-3163353661.html?x=0&.v=1

When we get FDA approval and we are very close now this stock will be worth at least $5.00 to $10.00 a share based on the market cap of all the other pharma stocks


Institutional buyers link:

http://www.mffais.com/anx


ANX Conference 01.12.210 http://www.onemedplace.com/database/list/cid/946
http://www.onemedplace.com/onemedforum/companies.php

This stock can go sometime above $20.00 over night
That would put his as a 30-45 bagger at todays price.

According to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. If approved by the U.S. Food and Drug Administration (FDA), the market for the Company’s drug candidates has a potential to reach more than $1.0 billion at market saturation.

Pharmaceutical companies with revenue of more than $1 billion include Cephalon Inc. (Nasdaq: CEPH), which trades at a market capitalization of $4.73 billion, and King Pharmaceuticals (Nasdaq: KG), which trades at a market capitalization of $3.15 billion. As of January 6, ANX trades at a market capitalization of $50.7 million.

The Company is in the process of commercializing two drug-therapy candidates in late stages of Food and Drug administration (FDA) clinical trials in the United States. The Company’s two candidates include ANX-530 (vinorelbine emulsion) and ANX-514 (docetaxel emulsion), formulated to enhance certain standard-of-care chemotherapy drugs. The Company also states that ANX-530 and ANX-514 are safer, more convenient and less expensive than Navelbine and Taxotere, two drug therapies currently marketed.

The Company’s strategy is to take advantage of an effective lifecycle-management technique of reformulating existing successfully marketed drug therapies. Of the top 50 pharmaceutical companies, more than 40% of all drug therapies produced have been reformulated to extend the life of existing marketed drugs between the years 2002 and 2005. Patent expirations and competition are threats to all pharmaceutical companies. Modified and improved existing products have become an important technique as a method of improving revenue stream for longer time periods.

The Company believes that chemotherapy drugs Navelbine and Taxotere have limitations that can be improved upon with its novel technologies. A new formulation of these two popular standard-of-care drug therapies is expected to reduce side-effects, negative results and medical complications of patients suffering from cancer.

The Company has attracted capital from Icahn Capital Management, Carl Icahn (as an individual), Barclays Global Investors UK Holdings, Vanguard Group among other well-know investors and group holding companies.

Carl Icahn - Current Portfolio thru 9-30-09 (ANX Holding)
http://www.gurufocus.com/holdings.php?GuruName=Carl+Icahn

Link to pre-market:

http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?selected=ANX&mkttype=pre&symbol=NEXM&symbol=MSFT&symbol=SLF&symbol=ANX

http://daytradingstockblog.blogspot.com/2010/01/stocks-to-buy-11310-january-13-2010.html

Adventrx Pharmaceuticals, Inc. (ANX) - Adventrx Pharmaceuticals stock managed to trade above $0.50 briefly on Tuesday. Resistance is now located at $0.52. A close above $0.50 with heavy volume would be very bullish. This stock could break out big with any positive news.


nice.